Search form
Search
Login
Subscribe
Home
Country Intelligence
Industry Directory
Offsets / IC
Tenders
Australia
(6/week)
Haiti
(0/week)
Guyana
(0/week)
Honduras
(0/week)
Guatemala
(0/week)
View all
(6/week)
News
United States
(507/week)
Manufacturing
(335/week)
Energy
(278/week)
Technology
(347/week)
Other Energy
(240/week)
Events
About us
Who we are
Our People
Partners
Contact us
LinkedIn
Login
Twitter
Register
Home
News
Pexastimogene devacirepvec
Sep 16, 2019
SillaJen Defending Position Relating to Recent Sale of Stock by Employee
Aug 02, 2019
SillaJen Announces Conclusions From Interim Futility Analysis Of Phase 3 PHOCUS Trial in HCC
Jun 06, 2019
SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)
Mar 26, 2019
BioInvent and Transgene Extend Their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
Jan 09, 2019
Oncolytic Virus Cancer Therapy Pipeline Insights Report 2018: Some of the Emerging Products include Pexa-Vec of Transgene/SillaJen, Telomelsin of Oncolys, and Canerpaturev (TBI-1401) of Takara Bio
Oct 24, 2018
OncoSec Announces Publication of Data in Nature Gene Therapy Demonstrating the Ability of its Newly Optimized Intratumoral IL-12 Immunotherapy Platform to Increase Systemic Anti-tumor Responses in both Treated and Untreated Lesions
Sep 04, 2018
SillaJen and Lee's Pharmaceutical Announce First Patient Enrolled in the PHOCUS Trial in China Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer
Jan 29, 2018
SillaJen Announces First Patient Enrolled in the NCI-Sponsored Trial Evaluating Combination Therapy in Colorectal Cancer with SillaJen's Pexa-Vec Oncolytic Immunotherapy
Jan 22, 2018
SillaJen and ABL Europe Expand Strategic Manufacturing Collaboration for Oncolytic Virus Therapies
Aug 16, 2017
SillaJen Announces Collaboration with the National Cancer Institute for Development of Combination Therapy with SillaJen's pexastimogene devacirepvec (Pexa-Vec) Oncolytic Immunotherapy
Jul 21, 2017
SillaJen and Lee's Pharmaceutical Announce Approval by the China CFDA to Commence Phase 3 Clinical Trial for Oncolytic Immunotherapy, Pexa-Vec, in Liver Cancer
Latest News
Apr 19, 2024
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
Apr 19, 2024
Two Top Rating Agencies Reaffirm Metropolitan’s Strong Credit Ratings
Apr 19, 2024
Mativ Announces Conference Call to Discuss First Quarter 2024 Results
Apr 19, 2024
LSI Industries Acquires EMI Industries, Expanding Store Fixtures and Food Service Equipment Business
Apr 19, 2024
Anue Water Technologies Adds Four New Channel Partners to Serve Wastewater Treatment Customers in California...
Apr 19, 2024
Kermit Facility Operational Update
Apr 19, 2024
Les Européens cherchent, dans la douleur, des fonds pour leur défense
Apr 19, 2024
Danemark: les forces armées à l'épreuve de leur modernisation
View all News
Agenda
17
June
France
Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024, 17 - 21 June 2024, Parc des Expositions de Paris Nord Villepinte ZAC Paris Nord 2, 93420 Villepinte – France (Halls 5a – 5b – 6)
Eurosatory 2024 There can be no sustainable world without peace and security. Founded in 1967, the exhibition...
21
May
Paris Marriott Rive Gauche & Conference Center
Future Artillery, 21-23 May 2024, Paris Marriott Rive Gauche & Conference Center, France
DELIVERING FIRES IN THE MULTI-DOMAIN BATTLESPACE As artillery reasserts itself as the ‘King of Battlefield’ in the wake...
21
May
United Arab Emirates
ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR Abu Dhabi 2024, 21-23 May 2024, ADNEC (Abu Dhabi National Exhibition Centre), Abu Dhabi, Al Khaleej Al Arabi St - Al Rawdah - Al Ma'arid - Abu Dhabi, UAE
ISNR ACCELERATING TRANSFORMATION IN THE NATIONAL SECURITY ECOSYSTEM ISNR Abu Dhabi is the region’s most trusted...
View All Events